Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300 (IMAGE)
Caption
Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in Melbourne, Australia
Credit
Ben Tran
Usage Restrictions
None
License
Licensed content